Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 6/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2897789 | 0.77 | MAPT (0.42) | GRM5GSK3BMAPT | |
| SCHEMBL2895112 | 0.77 | MAPT (0.42) | GRM5GSK3BMAPT | |
| SCHEMBL5480847 | 0.68 | GRM5 (0.42) | GRM5 | |
| SCHEMBL3453428 | 0.68 | MAPT (0.48) | MAPT | |
| SCHEMBL2077223 | 0.65 | MAPT (0.55) | MAPT | |
| SCHEMBL12835716 | 0.63 | PDE10A (0.43) | GRM5MAPT | |
| SCHEMBL5485198 | 0.63 | MAPT (0.44) | MAPT | |
| SCHEMBL1514268 | 0.63 | PDE10A (0.43) | GRM5MAPT | |
| SCHEMBL6598196 | 0.63 | MAPT (0.51) | MAPT | |
| SCHEMBL13036137 | 0.63 | MAPT (0.49) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | disclosed |
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | disclosed |
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | GRM5, GRM1, GRM3 | GRM5 1/4885GSK3B 3332/4885MAPT 1549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.